EU approves Abilify Maintena for Schizophrenia- Lundbeck/Otsuka

Lundbeck and Otsuka announced marketing authorisation approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of Schizophrenia in adult patients stabilised with oral aripiprazole. Abilify Maintena reduces the risk of relapse relative to placebo over the long-term and provides effective treatment of Schizophrenia. It has a tolerability profile similar to oral aripiprazole, and demonstrated statistically significant benefits on patients' personal and social functioning as compared to placebo.

93% of patients treated with Abilify Maintena were extremely, very or somewhat satisfied with their treatment at the end of the double-blind treatment phase.